Healthcare Biz Rewind: Nanosphere’s BAND WAGON, Arena On SHOPPING List
The June FDA approval of Nanosphere’s (NASDAQ:NSPH) bloodstream infection test, and subsequent jump in shares has prompted Roth Capital to upgrade from Neutral to Buy, with a price target of $4.50. Jefferies upgraded to stock last week for much the same reasons.
Don’t Miss: Is This Manufacturing Partner BETRAYING Apple?
Drug developer Arena Pharmaceuticals (NASDAQ:ARNA) shares move up thanks to a Sunday Bloomberg article which discussed potential merger and acquisition interest, following the recent FDA approval of its Belviq weight-loss drug. Analysts speculate that GlaxoSmithKline (NYSE:GSK) and/or Japan’s Eisai could extend an offer.
Mako Surgical (NASDAQ:MAKO) shares bomb after hours Monday, following the firm’s lower sales guidance for the current year. The firm reports that after getting off to slow start for the year, it now projects the sales of only 42-48 RIO systems during the year – much below the 52-58 forecast in a prior guidance.
Don’t Miss: Will Investors Give RIM a Legal HEADACHE?
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.